Betaxolol (tablet): Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{SI}}
{{SI}}
{{EH}}
{{EH}}
{{drugbox |
| image=betaxolol.png
| IUPAC_name =1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(isopropylamino)propan-2-ol
| CAS_number = 63659-18-7
| ATC_prefix=C07
| ATC_suffix=AB05
| ATC_supplemental={{ATC|S01|ED02}}
| PubChem=2369
| ChemSpiderID=2279
| DrugBank=APRD00245
| C=18 | H=29 | N=1 | O=3
|molecular_weight = 307.428 [[gram|g]]/[[Mole (unit)|mol]]
|smiles = CC(C)NCC(O)COc1ccc(cc1)CCOCC2CC2
|bioavailability = 89%
|metabolism = [[Liver|Hepatic]]
|elimination_half-life = 14–22 hours
|excretion = [[Kidney|Renal]] (20%)
|pregnancy_AU = C
|pregnancy_US = C
|pregnancy_category =
|legal_status = Rx-only
|routes_of_administration = oral, [[ocular]]
}}
'''Betaxolol''' (trade names '''Betoptic''', '''Betoptic S''', '''Lokren''', '''Kerlone''') is a selective [[beta blocker|beta<sub>1</sub> receptor blocker]] used in the treatment of [[hypertension]] and [[glaucoma]]. Being selective for beta<sub>1</sub> receptors, it typically has fewer systemic [[adverse drug reaction|side effect]]s than non-selective beta-blockers, for example, not causing [[bronchospasm]] (mediated by beta<sub>2</sub> receptors) as [[timolol]] may.  Betaxolol also shows greater affininty for beta<sub>1</sub> receptors than [[metoprolol]]. In addition to its effect on the heart, betaxolol reduces the pressure within the eye ([[intraocular pressure]]). This effect is thought to be caused by reducing the production of the liquid (which is called the [[aqueous humor]]) within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the [[optic nerve]] and loss of vision in patients with elevated intraocular pressure due to [[glaucoma]].
Betaxolol was approved by the U.S. [[Food and Drug Administration]] (FDA) for ocular use as a 0.5% solution ('''Betoptic''') in 1985 and as a 0.25% solution ('''Betoptic S''') in 1989.
==Clinical uses==
* Oral: for the management of hypertension
* Ophthalmic: for the management of glaucoma
==Dosage==
* Oral: The initial dose in hypertension is ordinarily 10 mg once daily either alone or added to diuretic therapy.
* Ophthalmic: The recommended dose is one to two drops in the affected eye(s) twice daily.
==Contraindications==
* Hypersensitivity to the drug
* Patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure
==External links==
* [http://products.sanofi-aventis.us/kerlone/kerlone.pdf Kerlone prescribing information]
==See also==
[[Levobetaxolol]]
{{beta blockers}}
{{Antiglaucoma preparations and miotics}}
[[Category:Beta blockers]]
[[it:Betaxololo]]
[[pl:Betaksolol]]
<small>'''''Synonyms / Brand Names:''''' </small>
<small>'''''Synonyms / Brand Names:''''' </small>



Revision as of 15:12, 8 July 2009

WikiDoc Resources for Betaxolol (tablet)

Articles

Most recent articles on Betaxolol (tablet)

Most cited articles on Betaxolol (tablet)

Review articles on Betaxolol (tablet)

Articles on Betaxolol (tablet) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Betaxolol (tablet)

Images of Betaxolol (tablet)

Photos of Betaxolol (tablet)

Podcasts & MP3s on Betaxolol (tablet)

Videos on Betaxolol (tablet)

Evidence Based Medicine

Cochrane Collaboration on Betaxolol (tablet)

Bandolier on Betaxolol (tablet)

TRIP on Betaxolol (tablet)

Clinical Trials

Ongoing Trials on Betaxolol (tablet) at Clinical Trials.gov

Trial results on Betaxolol (tablet)

Clinical Trials on Betaxolol (tablet) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Betaxolol (tablet)

NICE Guidance on Betaxolol (tablet)

NHS PRODIGY Guidance

FDA on Betaxolol (tablet)

CDC on Betaxolol (tablet)

Books

Books on Betaxolol (tablet)

News

Betaxolol (tablet) in the news

Be alerted to news on Betaxolol (tablet)

News trends on Betaxolol (tablet)

Commentary

Blogs on Betaxolol (tablet)

Definitions

Definitions of Betaxolol (tablet)

Patient Resources / Community

Patient resources on Betaxolol (tablet)

Discussion groups on Betaxolol (tablet)

Patient Handouts on Betaxolol (tablet)

Directions to Hospitals Treating Betaxolol (tablet)

Risk calculators and risk factors for Betaxolol (tablet)

Healthcare Provider Resources

Symptoms of Betaxolol (tablet)

Causes & Risk Factors for Betaxolol (tablet)

Diagnostic studies for Betaxolol (tablet)

Treatment of Betaxolol (tablet)

Continuing Medical Education (CME)

CME Programs on Betaxolol (tablet)

International

Betaxolol (tablet) en Espanol

Betaxolol (tablet) en Francais

Business

Betaxolol (tablet) in the Marketplace

Patents on Betaxolol (tablet)

Experimental / Informatics

List of terms related to Betaxolol (tablet)

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Betaxolol (tablet)
Clinical data
Pregnancy
category
  • AU: C
  • US: C (Risk not ruled out)
Routes of
administration
oral, ocular
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability89%
MetabolismHepatic
Elimination half-life14–22 hours
ExcretionRenal (20%)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H29NO3
Molar mass307.428 g/mol
3D model (JSmol)

Betaxolol (trade names Betoptic, Betoptic S, Lokren, Kerlone) is a selective beta1 receptor blocker used in the treatment of hypertension and glaucoma. Being selective for beta1 receptors, it typically has fewer systemic side effects than non-selective beta-blockers, for example, not causing bronchospasm (mediated by beta2 receptors) as timolol may. Betaxolol also shows greater affininty for beta1 receptors than metoprolol. In addition to its effect on the heart, betaxolol reduces the pressure within the eye (intraocular pressure). This effect is thought to be caused by reducing the production of the liquid (which is called the aqueous humor) within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.

Betaxolol was approved by the U.S. Food and Drug Administration (FDA) for ocular use as a 0.5% solution (Betoptic) in 1985 and as a 0.25% solution (Betoptic S) in 1989.

Clinical uses

  • Oral: for the management of hypertension
  • Ophthalmic: for the management of glaucoma

Dosage

  • Oral: The initial dose in hypertension is ordinarily 10 mg once daily either alone or added to diuretic therapy.
  • Ophthalmic: The recommended dose is one to two drops in the affected eye(s) twice daily.

Contraindications

  • Hypersensitivity to the drug
  • Patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure

External links

See also

Levobetaxolol

Template:Antiglaucoma preparations and miotics

it:Betaxololo

Synonyms / Brand Names:

Adapted from the FDA Package Insert. Template:SIB